<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">healthcare</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение. Healthcare</journal-title><trans-title-group xml:lang="en"><trans-title>Healthcare</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1027-7218</issn><publisher><publisher-name>Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.65249/1027-7218-2026-9-24-34</article-id><article-id custom-type="elpub" pub-id-type="custom">healthcare-371</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАУЧНЫЕ ИССЛЕДОВАНИЯ И РАЗРАБОТКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SCIENTIFIC RESEARCH AND DEVELOPMENT</subject></subj-group></article-categories><title-group><article-title>Клиническая характеристика и влияние вакцинации  на тяжесть COVID-19 у госпитализированных пациентов  в различные периоды пандемии</article-title><trans-title-group xml:lang="en"><trans-title>Clinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1677-7334</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Литвинчук</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Litvinchuk</surname><given-names>D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Литвинчук Дмитрий Вадимович – доцент кафедры инфекционных болезней  с курсом повышения квалификации и переподготовки </p><p>Пр. Дзержинского, 83, 220083, г. Минск</p><p>Сл. тел. +375 17 334-14-62 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5298-8343</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Данилов</surname><given-names>Д. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Danilau</surname><given-names>D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Данилов Дмитрий Евгеньевич</p><p>г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5816-2166</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpov</surname><given-names>I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карпов Игорь Александрович</p><p>г. Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Белорусский государственный медицинский университет</institution><country>Belarus</country></aff><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2026</year></pub-date><volume>1</volume><issue>9</issue><fpage>24</fpage><lpage>34</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Литвинчук Д.В., Данилов Д.Е., Карпов И.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Литвинчук Д.В., Данилов Д.Е., Карпов И.А.</copyright-holder><copyright-holder xml:lang="en">Litvinchuk D., Danilau D., Karpov I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://healthcare.ejournal.by/jour/article/view/371">https://healthcare.ejournal.by/jour/article/view/371</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Проанализировать клиническую тяжесть COVID-19 у госпитализированных пациентов в различные периоды пандемии, а также влияние вакцинации на клиническое течение заболевания.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В одноцентровое ретроспективное когортное исследование (2020–2023) включены 11 203 пациента с COVID-19 (112 455 койко-дней госпитализации). Тяжесть течения COVID-19 оценивалась по четырехуровневой шкале дыхательной недостаточности («нет», «кислородная маска/канюли», «неинвазивная вентиляция легких» (НИВЛ), «инвазивная вентиляция легких» (ИВЛ)). Статистическое моделирование – байесовская иерархическая ординальная регрессия с ковариатами: возраст, индекс коморбидности Эликсхаузер, анамнез вакцинации, дыхательная недостаточность за предыдущий день заболевания, день пандемии, день заболевания. Статистический анализ осуществлен с помощью языков программирования R 4.6.0 и Stan 2.38.0.</p></sec><sec><title>Результаты</title><p>Результаты. 28-дневный кумулятивный риск дыхательной недостаточности составил в первую волну до 50 %, в период распространения варианта «Альфа» – до 80 %, варианта «Дельта» – более 90 % у невакцинированных и до 65 % у вакцинированных, в период преобладания вариантов «Омикрон» – 25 % и менее. В период преобладания варианта «Дельта» у невакцинированных коморбидных пациентов старшего возраста вероятность нахождения на НИВЛ/ИВЛ достигала 25–30 % против ≤ 4,5 % у вакцинированных; в такой же популяции в период преобладания вариантов «Омикрон» вероятность НИВЛ/ИВЛ – менее 1 %, однако до 20 % пациентов нуждались в кислородной маске/канюлях. После стандартизации на ковариаты модели вакцинация была ассоциирована со снижением кумулятивного риска дыхательной недостаточности в период с сентября 2021 г. по март 2022 г., с максимумом в декабре 2021 г.: -24,3 % (95 % ДИ (-17,6; -30,6 %)).</p></sec><sec><title>Заключение</title><p>Заключение. Установлены зависимость тяжести дыхательной недостаточности от периода пандемии COVID-19 и протективный эффект вакцинации у госпитализированных пациентов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0.</p></sec><sec><title>Results</title><p>Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, &gt; 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was &lt; 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)).</p></sec><sec><title>Conclusion</title><p>Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>варианты SARS-CoV-2</kwd><kwd>дыхательная недостаточность</kwd><kwd>вакцинация</kwd><kwd>байесовская статистика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>SARS-CoV-2 VOCs</kwd><kwd>respiratory failure</kwd><kwd>vaccination</kwd><kwd>Bayesian statistics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">WHO COVID-19 dashboard // World Health Organization. – URL: https://data.who.int/dashboards/covid19/summary (date of access: 07.08.2026).</mixed-citation><mixed-citation xml:lang="en">WHO. WHO COVID-19 dashboard. 2026. Available at: https://data.who.int/dashboards/covid19/summary (accessed: 07.08.2026).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rahimi, A. Genetics and genomics of SARS-CoV-2 : a review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection / A. Rahimi, A. Mirzazadeh, S. Tavakolpour // Genomics. – 2021. – Vol. 113, № 1. – doi: 10.1016/j.ygeno.2020.09.059.</mixed-citation><mixed-citation xml:lang="en">Rahimi A., Mirzazadeh A., Tavakolpour S. Genetics and genomics of SARS-CoV-2. Genom. 2021; 113(1). doi:10.1016/j.ygeno.2020.09.059.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England / E. Volz, S. Mishra, M. Chand [et al.] // Nature. – 2021. – Vol. 593, № 7858. – doi: 10.1038/s41586-021-03470-x.</mixed-citation><mixed-citation xml:lang="en">Volz E., Mishra S., Chand M., et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021; 593 (7858). doi:10.1038/s41586-021-03470-x.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hospital admission and emergency care attendance risk for SARS-CoV-2 Delta (B.1.617.2) compared with Alpha (B.1.1.7) variants of concern : a cohort study / K. A. Twohig, T. Nyberg, A. Zaidi [et al.] // The Lancet Infectious Diseases. – 2022. – Vol. 22, № 1. – P. 35–42.</mixed-citation><mixed-citation xml:lang="en">Twohig K.A., Nyberg T., Zaidi A., et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 Delta (B.1.617.2) compared with Alpha (B.1.1.7) variants of concern. Lancet Infect Dis. 2022; 22(1): 35–42.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant / D. Tian, Y. Sun, H. Xu, Q. Ye // Journal of Medical Virology. – 2022. – Vol. 94, № 6. – doi: 10.1002/jmv.27643.</mixed-citation><mixed-citation xml:lang="en">Tian D., Sun Y., Xu H., Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol. 2022; 94(6). doi:10.1002/jmv.27643.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages : a systematic review and metanalysis / P. Relan, N.V. Motaze, K. Kothari [et al.] // BMJ Global Health. – 2023. – Vol. 8, № 7. – doi: 10.1136/bmjgh-2023-012328.</mixed-citation><mixed-citation xml:lang="en">Relan P., Motaze N.V., Kothari K., et al. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages. BMJ Glob Health. 2023; 8(7). doi:10.1136/bmjgh-2023-012328.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Increased risk of hospitalisation and death with the Delta variant in the USA / E. Bast, F. Tang, J. Dahn, A. Palacio // The Lancet Infectious Diseases. – 2021. – Vol. 21, № 12. – doi: 10.1016/S1473-3099(21)00685-X.</mixed-citation><mixed-citation xml:lang="en">Bast E., Tang F., Dahn J., Palacio A. Increased risk of hospitalisation and death with the Delta variant in the USA. Lancet Infect Dis. 2021; 21(12). doi:10.1016/S1473-3099(21)00685-X.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods – United States, April 2020 – June 2022 / S. Adjei, K. Hong, N.A.M. Molinari [et al.] // MMWR Morbidity and Mortality Weekly Report. – 2022. – Vol. 71, № 37. – doi: 10.15585/mmwr.mm7137a4.</mixed-citation><mixed-citation xml:lang="en">Adjei S., Hong K., Molinari N.A.M., et al. Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods – United States, April 2020 – June 2022. MMWR. 2022; 71(37). doi:10.15585/mmwr.mm7137a4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Характеристика эпидемического процесса COVID-19 в Республике Беларусь / А. М. Дашкевич, Н. Д. Коломиец // Клиническая инфектология и паразитология. – 2024. – Т. 13, № 1. – С. 70–80.</mixed-citation><mixed-citation xml:lang="en">Dashkevich A., Kolomiets N. Characteristics of the epidemic process of COVID-19 in the Republic of Belarus. Klinicheskaya infektologiya i parazitologiya. 2024; 13(1): 70–80. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mitchell, W. B. Thromboinflammation in COVID-19 acute lung injury / W. B. Mitchell // Paediatric Respiratory Reviews. – 2020. – Vol. 35. – P. 20–24.</mixed-citation><mixed-citation xml:lang="en">Mitchell W.B. Thromboinflammation in COVID-19 acute lung injury. Paediatr Respir Rev. 2020; 35: 20–24.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine : an interim analysis of a randomised controlled phase 3 trial in Russia / D. Y. Logunov, I. V. Dolzhikova, D. V. Shcheblyakov [et al.] // The Lancet. – 2021. – Vol. 397, № 10275. – doi: 10.1016/S0140-6736(21)00234-8.</mixed-citation><mixed-citation xml:lang="en">Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine. The Lancet. 2021; 397(10275). doi:10.1016/s0140-6736(21)00234-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19 : a systematic review and meta-analysis / K. Rahmani, R. Shavaleh, M. Forouhi [et al.] // Frontiers in Public Health. – 2022. – Vol. 10. – doi: 10.3389/fpubh.2022.873596.</mixed-citation><mixed-citation xml:lang="en">Rahmani K., Shavaleh R., Forouhi M., et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19. Front Public Health. 2022; 10. doi:10.3389/fpubh.2022.873596.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">A minimal common outcome measure set for COVID-19 clinical research / WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection // The Lancet Infectious Diseases. – 2020. – Vol. 20, № 8. – doi: 10.1016/S1473-3099(20)30483-7.</mixed-citation><mixed-citation xml:lang="en">WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8). doi:10.1016/s1473-3099(20)30483-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gasparini, A. comorbidity: an R package for computing comorbidity scores / A. Gasparini ; Biostatistics Research Group, Department of Health Sciences ; University of Leicester // Journal of Open Source Software. – 2018. – Vol. 3, № 23. – doi: 10.21105/joss.00648.</mixed-citation><mixed-citation xml:lang="en">Gasparini A. comorbidity: an R package for computing comorbidity scores. J Open Source Softw. 2018; 3(23). doi: 10.21105/joss.00648.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bayesian Data Analysis / A. Gelman, J. B. Carlin, H. S. Stern [et al.]. – 3rd ed. – Boca Raton : Chapman &amp; Hall/CRC, 2013. – 675 p.</mixed-citation><mixed-citation xml:lang="en">Gelman A., Carlin J.B., Stern H.S., et al. Bayesian Data Analysis. 3rd ed. Boca Raton: Chapman &amp; Hall/CRC; 2013. 675. doi: 10.1201/b16018.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bayesian transition models for ordinal longitudinal outcomes / M. D. Rohde, B. French, T. G. Stewart, F. E. Harrell Jr. // Statistics in Medicine. – 2024. – Vol. 43, № 18. – doi: 10.1002/sim.10133.</mixed-citation><mixed-citation xml:lang="en">Rohde M.D., French B., Stewart T.G., Harrell Jr. F.E. Bayesian transition models for ordinal longitudinal outcomes. Stat Med. 2024; 43(18). doi: 10.1002/sim.10133.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Stan modeling language user’s guide and reference manual (Version 2.39) / Stan Development Team. – URL: https://mc-stan.org (date of access: 07.08.2026).</mixed-citation><mixed-citation xml:lang="en">Stan Development Team. Stan modeling language user’s guide and reference manual (Version 2.39). Available at: https://mc-stan.org (accessed: 07.08.2026).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Burkner, P. C. Bayesian item response modeling in R with BRMS and Stan / P. C. Burkner // Journal of Statistical Software. – 2021. – Vol. 100, № 5. – P. 1–54.</mixed-citation><mixed-citation xml:lang="en">Burkner P.C. Bayesian item response modeling in R with BRMS and Stan. J Stat Softw. 2021; 100(5): 1–54.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">R: a language and environment for statistical computing / R Core Team. – Vienna : R Foundation for Statistical Computing, 2026. – URL : https://www.R-project.org (date of access: 07.08.2026).</mixed-citation><mixed-citation xml:lang="en">R Core Team. R: a language and environment for statistical computing. Vienna : R Foundation for Statistical Computing; 2026. Available at: https://www.R-project.org. (accessed: 07.08.2026).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
